MoMo should be helped by 19 new PRCA case mainly due to JnJ's Eprex-total 160-All analysts raise forcasts-What is confusing the investors is amgn stating growth in "02 reduced from low 20's to mid teens-This not due to sales -but to write off of Imnx charges-Sales of main products increasing in 30%+ range.Sharer now says in bloomberg interview that FDA will inspect in early nov(RI),So FDA ok could come dec 23rd @ PDUFA meet-Enbrel inventory will be ready for immediate distribution.